Loading
A phase 2 trial of Selpercatinib in thyroid cancer, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation is a phase 2 interventional study registered as NCT04280081 by Eli Lilly and Company, with 77 participants enrolled, started 2020-03-16 and due to reach its primary completion in 2021-03-25. Interventions recorded: Selpercatinib. Conditions listed: Solid Tumor, Medullary Thyroid Cancer. Results were posted on ClinicalTrials.gov in 2022; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
77 enrolled.
95% CI 48.2 to 85.7; Figures from the ClinicalTrials.gov results section (first posted 2022-06-02), not from a publication · 95% CI 2.5 to 100.0 · 95% CI 36.9 to 76.6
Source95% CI 50.7 to 79.1; Figures from the ClinicalTrials.gov results section (first posted 2022-06-02), not from a publication · 95% CI 2.5 to 100.0 · 95% CI 38.9 to 76.5
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC), Overall Response (CR/PR)primary | RET Fusion Positive Non-small Cell Lung Cancer (NSCLC) Cohort 1 | 26 | 69.2% | - | - | link |
| RET Fusion Positive Thyroid Cancer (TC) Cohort 1 | 1 | 100% | ||||
| RET Mutant Medullary Thyroid Cancer (MTC) Cohort 2 | 26 | 57.7% | ||||
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC, Overall Response (CR/PR)primary | Non-small Cell Lung Cancer (All NSCLC) | 47 | 66% | - | - | link |
| Thyroid Cancer (All TC) | 1 | 100% | ||||
| Medullary Thyroid Cancer (All MTC) | 29 | 58.6% |
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer, Small-molecule kinase inhibitors.
Shares Medullary thyroid cancer, Thyroid cancer.
Shares Medullary thyroid cancer, Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer.
Shares Selpercatinib, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Selpercatinib, Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Shares Medullary thyroid cancer, Thyroid cancer.
Shares Medullary thyroid cancer, Selpercatinib.
Shares Medullary thyroid cancer, Thyroid cancer.